Home
Home

JAK inhibitors

[video]AbbVie's New Crohn's Disease Drug Candidate

[video]AbbVie's New Crohn's Disease Drug Candidate
Motley Fool

Can JAK Inhibitors Challenge Biologics?

Can JAK Inhibitors Challenge Biologics?
Motley Fool

Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis
Yahoo

J&J and Astellas Collaborate

J&J and Astellas Collaborate
Yahoo/Zacks

Pfizer's Success With Its JAK Inhibitor

Pfizer's Success With Its JAK Inhibitor
Seeking Alpha

Will New RA Therapies Cause a Paradigm Shift?

Will New RA Therapies Cause a Paradigm Shift?
Pharma Live

AstraZeneca Set To Gain From New Asthma Drug

AstraZeneca Set To Gain From New Asthma Drug
Seeking Alpha

AstraZeneca, Rigel Pharmaceuticals sign license agreement for R256

AstraZeneca, Rigel Pharmaceuticals sign license agreement for R256
Yahoo/Fly on the Wall

Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis

Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Yahoo

Cell Therapeutics' JAK2 Inhibitor Acquisition Is A Smart Pick-Up

Cell Therapeutics' JAK2 Inhibitor Acquisition Is A Smart Pick-Up
Seeking Alpha